Clinical trials
Hepatocellular Carcinoma clinical trials
Below are recruiting hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 591 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07417800Recruiting
Predicting liver cancer treatment after surgery
This study uses digital scans of your tumor tissue and CT/MRI images to build a computer model that helps predict whether you might need extra treatment (adjuvant therapy) after liver cancer surgery. The goal is to use your own tissue and scan data to personalize follow-up care.
Hangzhou, ZhejiangAges 18 years+ - NCT07285044RecruitingPhase 2
Home cancer treatment program for Florida panhandle residents
This study tests whether people with certain cancers can safely receive their regular intravenous treatments at home instead of coming to the clinic. It aims to make treatment more convenient and improve satisfaction, especially for those living in the Florida Panhandle.
Jacksonville, FloridaAges 18 years+ - NCT06334965Recruiting
Studying liver cancer response to targeted radiation therapy
This trial is for people with liver cancer (hepatocellular carcinoma) who are about to receive a type of internal radiation therapy called TARE (also known as radioembolization). Researchers want to learn more about how the cancer responds to this treatment using scans and biopsies. You might be a good fit if you have not had any prior treatment for your liver cancer.
ClichyAges 18 years+ - NCT06999837Recruiting
PSMA PET/CT scan for liver cancer (HCC)
This study tests a new type of PET/CT scan (called PSMA) that may help doctors see liver cancer (HCC) better. The scan takes detailed images to track how the cancer behaves, which could help choose the best treatment.
ClichyAges 18 years+ - NCT07291141Recruiting
MRI vs. Ultrasound for Liver Cancer Detection in Cirrhosis
This study compares MRI and ultrasound to see which is better at finding liver cancer early in people with liver cirrhosis. It also looks at body composition and other factors that could lead to worsening liver function.
Linköping, Select A State Or ProvinceAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT06789198RecruitingPhase 1
Peptide Vaccine for Fibrolamellar Cancer and Related Tumors
This trial tests a vaccine designed to target cancer cells with a specific genetic change (DNAJB1-PRKACA). It is for people whose fibrolamellar liver cancer or other tumors with this change are in complete remission after prior treatment, to help prevent the cancer from coming back.
TübingenAges 12 years+ - NCT05594927RecruitingPhase 3
Test icaritin vs huachansu for advanced liver cancer with poor health
This Phase 3 trial compares two medicines—icaritin soft capsules versus huachansu tablets—as first treatment for unresectable hepatocellular carcinoma (HCC) that has “poor prognosis” blood test markers. It aims to see which option works better and is safer for people who can’t use standard first-line treatments or don’t want them.
Nanchang, JiangxiAges 18 years+ - NCT03368651RecruitingPhase 3
Testing a pre-surgery infusion to improve liver cancer outcomes
This trial tests whether giving medicine directly into the liver blood vessels before surgery can improve survival for people with liver cancer that has a blockage (tumor in the portal vein). It compares this approach plus surgery versus surgery alone in a randomized study.
Guangzhou, GuangdongAges 18–75 - NCT07298577Enrolling by invitation
Using blood test and ultrasound to find early liver cancer in Asia
This study tests whether adding a simple blood test (GAAD score) to a routine liver ultrasound can find early-stage liver cancer sooner in people with chronic liver conditions. It aims to improve detection in Asian populations at risk.
Bangkok Noi, BangkokAges 18 years+ - NCT07469319Recruiting
Liver cancer screening for people with cirrhosis
This study tests whether offering an ultrasound and a blood test (alpha-fetoprotein) every 6 months can help find liver cancer early in people with cirrhosis (scarred liver) caused by conditions other than hepatitis B or C. The goal is to reduce deaths from liver cancer in this group.
Aarhus, Central JutlandAges 40–79 - NCT03895359RecruitingPhase 3
Chemo plus targeted radiation versus chemo alone for liver cancer
This trial compares two treatments for liver cancer that can’t be removed with surgery: chemo through the liver (TACE) alone versus TACE plus a precise radiation treatment (SBRT). It may help people whose cancer stays in the liver but can’t be operated on, by testing whether adding focused radiation improves outcomes.
London, OntarioAges 18 years+ - NCT05024214RecruitingPhase 1/Phase 2
Test of envafolimab plus lenvatinib for advanced solid tumors
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
Bengbu, AnhuiAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT06687941RecruitingPhase 1
Trial of AST-201 for GPC3-positive advanced solid tumors
This trial tests a new drug called AST-201 for people with advanced solid tumors that have a specific protein (GPC3). The study aims to see how safe and well-tolerated the drug is, and how the body processes it.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT06899152Recruiting
New tests to track liver health during radiation for liver cancer
This study tests new blood tests and MRI scans to see how well your liver works during radiation therapy for liver cancer. It may help doctors better plan treatment and monitor your liver health.
The Bronx, New YorkAges 18 years+ - NCT07275073RecruitingPhase 1
JMT106 for advanced solid tumors
This trial is testing a new medicine called JMT106 for people with advanced solid tumors (cancers that have spread or can't be removed). It's for patients whose cancer has not responded to or can't use other treatments, and who have not had a therapy targeting a specific protein (GPC3) before.
ZhejiangAges 18 years+ - NCT07348211RecruitingPhase 1
Study of SIM0610 for advanced solid tumors
This trial tests a new drug called SIM0610 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT03253536Recruiting
Quality of life study after precise liver radiation
This study follows people with liver cancer (hepatocellular carcinoma) to see how their quality of life changes after a focused form of radiation called stereotactic ablative radiation therapy. It does not appear to test a new drug—rather, it measures patient-reported well-being after treatment.
Munich, BavariaAges 18 years+ - NCT04792463Recruiting
BAP1 gene cancer-risk study and family cancer patterns
This study looks at how the BAP1 gene affects cancer risk and what cancers people develop, including within families. You may be able to join if you have a known BAP1-related mutation, a strong family cancer history, or a concerning cancer pattern linked to BAP1.
Columbus, OhioAges Any age - NCT06027086RecruitingPhase 1/Phase 2
Combination drug therapy for advanced fibrolamellar carcinoma
This trial tests a new combination of two drugs—DRP-104 and durvalumab—to see if they can shrink or slow advanced fibrolamellar carcinoma, a rare liver cancer. It is for patients whose cancer has gotten worse even after immunotherapy treatment.
Baltimore, MarylandAges 12 years+ - NCT06363006RecruitingPhase 1
Cardonizumab plus TKI for advanced liver cancer after prior treatment
This trial tests a combination of an immunotherapy drug (Cardonizumab) and a targeted therapy pill (TKI) for people with advanced liver cancer whose prior treatment has stopped working. The goal is to see if this second-line combination can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07075120RecruitingPhase 1
Immunotherapy and radiation for advanced liver cancer
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
Honolulu, HawaiiAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma?
- Yes. Clin2 currently lists 591 recruiting hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.